multipl
sclerosi
ms
cell
driven
autoimmun
diseas
central
nervou
system
cn
despit
associ
epsteinbarr
viru
ebv
viral
infect
promot
ms
remain
unclear
howev
increas
evid
cn
continu
survey
virusspecif
cell
protect
reactiv
neurotrop
virus
discuss
viral
infect
could
lead
breakdown
selftoler
genet
predispos
individu
reactiv
virus
cn
could
induc
recruit
autoaggress
virusspecif
cell
subset
caus
relaps
progress
disabl
disturb
immun
surveil
ms
would
explain
sever
experiment
find
import
implic
prognosi
therapi
ms
common
inflammatori
autoimmun
disord
cn
character
destruct
protect
myelin
sheath
neuron
result
macroscop
lesion
brain
caus
progress
disabl
ms
subdivid
relapsingremit
rr
primari
progress
pp
secondari
progress
sp
ie
rr
subtyp
worsen
time
spm
form
rrm
domin
form
diseas
onset
character
acut
clinic
attack
follow
appar
diseas
stabil
symptom
allevi
sever
therapi
patient
benefici
effect
diseas
may
evolv
sp
form
ppm
spm
remain
difficult
treat
also
mechanist
poorli
understood
etiolog
ms
still
unknown
genet
environment
factor
contribut
risk
develop
ms
major
genet
risk
factor
map
human
leukocyt
antigen
hla
gene
cluster
strongest
risk
confer
class
ii
region
princip
function
mhc
class
ii
protein
present
peptid
ligand
f
f
lymphocyt
cell
consequ
believ
key
pathogen
role
ms
howev
mhc
class
cluster
regul
cytotox
lymphocyt
respons
contain
polymorph
region
associ
protect
ms
sever
gene
huge
bodi
evid
suggest
viral
infect
promot
ms
howev
singl
causal
viru
identifi
multipl
virus
could
promot
ms
via
bystand
effect
molecular
mimicri
establish
pathogen
mechan
select
autoimmun
diseas
also
well
document
ms
contribut
ms
pathogenesi
still
unclear
bystand
activ
upon
viral
infect
could
involv
gener
autoreact
potenti
encephalitogen
helper
th
central
memori
cm
polymorph
associ
ms
involv
immun
respons
particular
activ
homeostasi
cell
consist
concept
ms
celldriven
autoimmun
diseas
import
environ
determin
whether
genet
suscept
individu
develop
ms
underlin
studi
monozygot
twin
genet
suscept
individu
migrat
lowto
highrisk
area
strongest
environment
risk
factor
vitamin
defici
smoke
viral
infect
interestingli
infect
helminth
shown
protect
effect
among
viral
infect
ebv
show
strongest
associ
estim
ebvinduc
infecti
mononucleosi
increas
risk
ms
similar
degre
strongest
genet
risk
factor
addit
ebv
sever
virus
implic
ms
particular
neurotrop
virus
includ
human
herp
herp
zoster
viru
john
cunningham
viru
jcv
also
endogen
retrovirus
base
evid
possibl
viral
etiolog
ms
propos
continu
stimul
intens
research
field
f
f
see
outstand
question
risk
lifethreaten
jcvinduc
progress
multifoc
leukoencephalopathi
pml
patient
ms
undergo
therapi
natalizumab
therapeut
antibodi
bind
adhes
receptor
block
lymphocyt
migrat
cn
highlight
import
antivir
immun
surveil
cn
inde
presenc
lymphat
system
cn
challeng
view
cn
immuneprivileg
site
wide
accept
cn
survey
protect
antivir
cell
f
f
box
given
updat
view
immun
respons
cn
discuss
differ
model
viral
infect
could
promot
ms
illustr
defect
antivir
immun
surveil
could
drive
forc
pathogenesi
although
epidemiolog
data
clearli
indic
viral
infect
critic
risk
factor
ms
underli
mechan
poorli
understood
anim
model
induc
experiment
autoimmun
encephalomyel
eae
absenc
viral
infect
prime
pathogen
cell
myelin
antigen
wide
use
studi
neuroinflamm
ms
selftoler
broken
model
adjuv
cfa
contain
kill
mycobacteria
intracellular
pathogen
potent
activ
innat
immun
system
altern
model
ms
demyelin
induc
neurotrop
virus
mous
hepat
viru
theiler
murin
encephalomyel
viru
tmev
less
studi
enabl
research
address
viral
infect
could
promot
ms
tmev
induc
chronic
inflamm
demyelin
brain
importantli
virusspecif
myelinreact
effector
cell
gener
ms
model
thu
antivir
immun
respons
cn
result
breakdown
selftoler
myelin
antigen
box
cn
immun
privileg
notion
cn
tolerogen
immuneprivileg
site
immun
reaction
occur
peripher
tissu
ineffici
slow
stem
semin
studi
transplant
allogen
tissu
slowli
reject
brain
unless
anim
immun
previous
addit
well
known
entri
macromolecul
immun
cell
cn
blood
restrict
bbb
recent
cn
also
believ
lack
lymphat
drainag
howev
presenc
lymphat
system
mening
brain
occasion
reactiv
neurotrop
virus
suggest
cn
constantli
survey
immun
system
although
manner
limit
type
collater
tissu
damag
occur
ms
normal
prevent
regulatori
cell
treg
addit
virus
antivir
cell
also
lead
directli
damag
demyelin
cn
thu
viral
ms
model
highli
relev
less
studi
eae
one
reason
role
virus
ms
still
poorli
understood
use
myelin
antigen
induc
eae
consist
demyelin
brain
patient
ms
presenc
autoreact
cell
recogn
myelinderiv
antigen
restrict
major
ms
risk
allel
howev
myelinreact
cell
rare
found
similar
frequenc
peripher
blood
healthi
individu
patient
ms
howev
myelinreact
cell
proinflammatori
properti
patient
ms
healthi
donor
enrich
csf
patient
ms
shortli
attack
nevertheless
myelinderiv
antigen
probabl
relev
selfantigen
ms
particular
pathogen
cell
ms
may
degener
cell
receptor
tcr
crossreact
sever
structur
relat
selfpeptid
potenti
even
directli
backbon
mhc
molecul
autoreact
cell
high
pathogen
potenti
could
activ
antigenpres
cell
apc
express
mhc
class
ii
costimulatori
molecul
final
virusspecif
cell
could
also
caus
collater
damag
cn
follow
antivir
immun
respons
particular
crossreact
relev
selfantigen
due
phenomenon
known
molecular
mimicri
molecular
mimicri
frequent
discuss
mechan
virus
could
induc
autoimmun
ms
box
excel
review
publish
topic
tcr
recogn
sever
similar
peptid
crossreact
relev
autoimmun
might
exploit
pathogen
virus
avoid
recognit
adapt
immun
system
inde
autoreact
cell
either
delet
thymu
render
unrespons
peripheri
even
redirect
treg
lineag
induc
domin
immun
suppress
viral
protein
contain
peptid
sequenc
similar
selfprotein
host
case
ms
molecular
mimicri
myelin
basic
protein
mbp
ebv
latenc
antigen
well
document
sinc
f
f
cell
clone
isol
patient
ms
could
activ
mbpand
peptid
addit
cell
crossreact
mbp
identifi
molecular
mimicri
might
also
exploit
interestingli
commens
bacteria
known
essenti
autoimmun
demyelin
cell
express
tcr
crossreact
mbp
common
bacteri
peptid
abl
induc
mslike
diseas
human
mice
howev
molecular
mimicri
larg
accept
drive
forc
autoimmun
diseas
streptococcusdriven
rheumat
fever
relev
ms
still
debat
moreov
glossari
bloodbrain
barrier
bbb
compris
two
physic
barrier
endotheli
cell
parenchym
base
membran
strongli
limit
access
macromolecul
cell
cn
parenchyma
endotheli
parenchym
basement
membran
defin
inner
outer
limit
perivascular
space
fill
cerebrospin
fluid
csf
drain
macromolecul
immun
cell
deep
cervic
lymph
node
central
memori
cm
effector
memori
em
cell
distinguish
express
human
express
mice
cell
home
preferenti
lymphoid
nonlymphoid
tissu
respect
em
produc
higher
level
proinflammatori
cytokin
cm
cm
em
contain
cell
moreov
cm
express
adhes
chemokin
receptor
enabl
home
cn
clinic
isol
syndrom
ci
first
attack
classifi
ci
unless
ms
diagnos
follow
demonstr
lesion
dissemin
space
time
mri
occurr
second
clinic
attack
experiment
autoimmun
encephalopathi
eae
moststudi
anim
model
ms
cn
inflamm
disabl
induc
immun
myelin
antigen
adjuv
adopt
transfer
activ
myelinspecif
th
cell
progress
multifoc
leukoencephalopathi
pml
often
fatal
demyelin
cn
diseas
caus
uncontrol
jcv
replic
larg
limit
individu
cell
respons
impair
patient
aid
ms
cn
immun
surveil
inhibit
natalizumab
helper
helper
cell
uncommit
cell
differenti
upon
antigen
activ
influenc
differ
cytokin
ifngproduc
cell
cell
induc
mediat
protect
intracellular
pathogen
virus
cell
induc
tgfb
il
mimicri
evolutionari
process
wherebi
one
organ
acquir
similar
anoth
organ
obtain
surviv
advantag
molecular
mimicri
phenomenon
wherebi
molecul
pathogen
particular
peptid
similar
peptid
host
cell
mount
immun
respons
activ
foreign
peptid
normal
react
selfpeptid
latter
ensur
combin
central
peripher
toler
mechan
lead
delet
highli
autoreact
cell
thymu
ensur
cell
intermedi
autoreact
aberrantli
activ
peripheri
molecular
mimicri
hypothesi
autoimmun
propos
cell
caus
autoimmun
diseas
follow
antipathogen
immun
respons
crossreact
selfpeptid
healthi
uninfect
tissu
molecular
mimicri
thought
drive
forc
exampl
streptococcusdriven
rheumat
fever
also
document
protein
ebv
myelin
basic
protein
ms
vital
deal
extracellular
bacteria
fungi
cell
coproduc
ifng
respond
intraand
extracellular
pathogen
found
cell
respons
antigen
deriv
ebv
jcv
myelin
larg
confin
helper
type
cell
subset
patient
ms
therefor
f
f
cell
respons
ms
virus
myelin
antigen
predominantli
mediat
distinct
th
cell
subset
rather
virusspecif
cell
clone
crossreact
selfantigen
nevertheless
cell
isol
csf
react
autolog
apc
absenc
exogen
antigen
might
crossreact
peptid
virus
bacteria
thu
although
molecular
mimicri
like
contribut
ms
risk
confer
infect
mechan
also
like
import
f
f
addit
cell
b
cell
cell
also
involv
human
ms
evidenc
presenc
cerebrospin
fluid
csf
demyelin
brain
lesion
patient
particular
product
oligoclon
antibodi
csf
highli
characterist
ms
therefor
use
support
criterion
diagnosi
moreov
b
cell
deplet
rituximab
reduc
relaps
patient
rrm
therapeut
effect
could
reflect
capac
b
cell
present
antigen
pathogen
cell
sinc
rituximab
deplet
plasma
cell
antibodi
level
poorli
affect
howev
rituximab
could
also
inhibit
viral
deliveri
brain
b
cell
repres
cellular
reservoir
ebv
jcv
therefor
like
vehicl
virus
pass
across
bloodbrain
barrier
bbb
interestingli
secondari
progress
ms
character
tertiari
mening
lymphoid
structur
might
contain
infect
b
cell
constant
local
sourc
ebv
oligoclon
antibodi
csf
first
thought
repres
nonsens
igg
physiolog
relev
matter
debat
howev
sever
group
found
could
react
neurotrop
virus
conflict
result
publish
ebvspecif
antibodi
csf
sever
group
report
antibodi
measl
rubella
herp
zoster
virus
known
mrz
reaction
present
patient
ms
might
predict
whether
patient
clinic
isol
syndrom
ci
go
develop
ms
presenc
virusspecif
antibodi
csf
suggest
demyelin
ms
accompani
antivir
immun
respons
consist
notion
ebvspecif
f
f
cell
specif
expand
csf
patient
ms
cell
interact
lytic
infect
b
cell
identifi
ms
brain
lesion
howev
whether
presenc
ebv
brain
lesion
characterist
ms
debat
note
sever
virus
persist
latent
stage
neurotrop
thu
might
present
brain
moreov
herp
simplex
viru
hsv
shown
trigger
gener
autoantibodi
brain
neurotrop
virus
jcv
herp
zoster
propos
role
ms
direct
detect
viral
nucleic
acid
limit
minor
patient
local
viral
reactiv
parenchyma
might
necessarili
detect
csf
standard
techniqu
note
mani
virus
includ
ebv
jcv
effici
control
healthi
individu
caus
lifethreaten
infect
immunocompromis
individu
find
rais
question
whether
patient
ms
mount
somehow
alter
immun
respons
virus
particular
tolerogen
environ
cn
associ
mhc
class
polymorph
protect
consist
ineffici
antivir
cytotox
immun
respons
patient
ms
howev
far
antivir
immun
respons
patient
ms
found
either
normal
even
increas
case
ebv
patient
ms
treat
strong
immun
suppress
notabl
except
natalizumab
experi
increas
viral
reactiv
nevertheless
qualit
approach
might
requir
monitor
antivir
immun
respons
patient
ms
exampl
antivir
cell
respons
normal
measur
ifng
product
howev
central
memori
cell
cm
could
perform
antivir
immun
surveil
cn
see
produc
limit
amount
ifng
effici
expand
viral
antigen
summari
role
differ
viral
infect
ms
debat
research
need
understand
regul
antivir
immun
respons
patient
ms
might
impact
pathogenesi
diseas
progress
cell
migrat
lymph
node
cn
requir
antivir
immun
surveil
relaps
requir
featur
cell
induc
relaps
also
perform
antivir
immun
surveil
capac
migrat
lymph
node
cn
access
cn
immun
cell
tightli
control
brain
separ
blood
bbb
migrat
leukocyt
differ
tissu
control
specif
adhes
molecul
chemokin
receptor
known
key
adhes
molecul
cn
entri
although
cell
home
cn
independ
nevertheless
natalizumab
inhibit
relaps
promot
jcv
reactiv
pml
patient
ms
indic
critic
role
cn
home
pathogen
protect
antivir
cell
integrin
activ
insideout
signal
human
cell
differ
chemokin
receptor
induc
adhes
howev
relev
chemokin
receptor
cn
home
ms
debat
one
candid
induc
tgfb
proinflammatori
cytokin
stabli
express
human
cell
propos
allow
access
cell
cn
via
lumbar
spinal
cord
upon
eae
induct
steadi
state
via
choroid
plexu
pave
way
consecut
recruit
addit
cell
upon
ensu
inflamm
inflammatori
chemokin
receptor
implic
cn
home
ms
two
chemokin
receptor
select
express
ifngproduc
cell
fight
virus
ligand
induc
upon
viral
infect
canon
respons
interferon
final
also
implic
cell
migrat
cn
ms
somewhat
surpris
sinc
key
function
cell
mediat
home
cm
lymph
node
home
f
f
effector
memori
cell
em
nonlymphoid
tissu
predominantli
mediat
inflammatori
chemokin
receptor
howev
relev
fraction
cm
express
suggest
cm
shuttl
lymph
node
cn
inde
cell
highli
abund
csf
patient
ms
ligand
express
cn
includ
ms
lesion
express
chemokin
receptor
dynam
antigenactiv
cell
therefor
uncertain
whether
express
reliabl
identifi
cm
em
cn
patient
activ
ms
nevertheless
encephalitogen
role
cm
ms
suggest
therapeut
effici
fingolimod
sequest
cm
lymph
node
spare
em
furthermor
csf
patient
natalizumabtr
ms
cell
deplet
cell
strongli
enrich
sinc
patient
stabl
diseas
find
consist
view
cm
deriv
cell
drive
pathogen
cn
inflamm
ms
ligand
also
crucial
protect
antivir
cell
respons
cn
mice
suggest
cn
migrat
antivir
pathogen
cell
reli
similar
mechan
summari
differ
migratori
rout
cell
reach
cn
describ
appear
critic
antivir
immun
surveil
relaps
ident
relev
chemokin
receptor
uncertain
eae
model
instrument
identif
proinflammatori
cytokin
drive
pathogen
cn
inflamm
semin
find
autoimmun
close
relat
cytokin
nonredund
pathogen
role
potent
induc
cell
wherea
induc
matur
cell
suggest
cell
key
pathogen
cell
concept
rapidli
expand
human
organspecif
immunemedi
diseas
singl
nucleotid
polymorph
snp
reduc
signal
shown
strong
protect
effect
psoriasi
crohn
diseas
howev
similar
protect
effect
snp
found
ms
instead
polymorph
gene
locu
encod
subunit
show
strong
associ
interestingli
viral
enceph
induc
neurotrop
coronaviru
mice
enhanc
morbid
associ
enhanc
cell
ifng
product
thu
nonredund
pathogen
role
eae
appear
relev
viral
ms
mous
model
possibl
also
human
ms
eae
model
differ
cell
subset
includ
cell
could
induc
pathogen
neuroinflamm
although
differ
characterist
cell
coproduc
ifng
high
pathogen
potenti
also
enrich
brain
lesion
patient
ms
human
induc
cell
also
convent
cell
andor
enhanc
bbb
permeabl
neurotox
potenti
addit
promis
result
obtain
clinic
trial
neutral
antibodi
rrm
howev
defici
neither
ifng
complet
prevent
f
f
eae
induct
gmcsf
absolut
requir
propos
pathogen
mechan
eae
dendrit
cell
dc
deriv
induc
cell
produc
gmcsf
turn
lead
recruit
activ
addit
myeloid
cell
gmcsfproduc
cell
also
abund
csf
patient
ms
gmcsf
appear
regul
differ
human
compar
f
f
mice
produc
cell
also
cell
summari
relev
differ
exist
regul
pathogen
key
proinflammatori
cytokin
includ
gmcsf
eae
viral
ms
model
patient
ms
altern
mechan
could
explain
pathogen
role
viral
infect
ms
bystand
activ
f
f
box
virus
potent
induc
matur
dc
consequ
upregul
mhc
costimulatori
molecul
thu
favor
activ
virusspecif
also
potenti
autoreact
cell
addit
lytic
virus
jcv
induc
death
myelinproduc
oligodendrocyt
induc
releas
box
bystand
activ
bystand
activ
process
wherebi
adapt
immun
respons
specif
pathogen
lead
activ
pathogenspecif
cell
also
bystand
cell
specif
pathogen
two
differ
mechan
describ
bystand
cell
activ
occur
tcrindepend
fashion
via
homeostat
cytokin
latter
allow
establish
memori
cell
antivir
f
f
cell
surviv
despit
high
number
new
effector
memori
cell
gener
protect
new
invad
pathogen
well
document
case
viral
infect
mice
tcrindepend
prolifer
induc
cytokin
f
f
document
human
second
bystand
cell
activ
via
tcr
pathogen
induc
dc
matur
thu
upregul
mhc
costimulatori
molecul
tcrdriven
bystand
activ
particularli
import
autoreact
cell
respons
modul
cytokin
present
myelinderiv
selfantigen
deep
cervic
lymph
node
dc
figur
inhibit
bystand
activ
autoreact
cell
task
treg
sever
treg
subset
appear
defect
patient
ms
moreov
msassoci
polymorph
gene
regul
cell
activ
suggest
th
cell
resist
suppress
howev
cell
high
activ
threshold
therefor
appear
like
autoreact
memori
cell
aberrantli
activ
importantli
healthi
individu
harbor
popul
autoreact
memori
cell
secret
respons
lowlevel
tcr
stimul
selfmhc
inhibit
prolifer
autoreact
cell
express
possibl
consequ
exposur
tgfb
steadi
state
thu
appear
close
relat
cell
distinct
autoreact
treg
express
also
distinguish
regulatori
cell
interestingli
autoreact
memori
cell
specif
recal
antigen
tetanu
toxoid
suggest
degener
tcr
specif
respons
optim
tcr
stimul
recal
antigen
behav
similar
way
convent
memori
cell
suggest
contribut
protect
recal
respons
healthi
individu
intriguingli
patient
rrm
expand
popul
autoreact
cell
express
coproduc
ifng
product
reduc
cell
suggest
autoreact
cell
pathogen
reduc
capac
inhibit
activ
respons
lowlevel
tcr
stimul
notabl
cell
induc
cell
precursor
respons
andor
proinflammatori
cytokin
produc
dc
respons
virus
convers
cell
ifngproduc
cell
also
occur
inflam
tissu
mice
vivo
addit
expand
cell
patient
ms
prolifer
myelin
antigen
produc
high
level
gmcsf
express
indic
cell
potenti
encephalitogen
consist
hypothesi
cm
cell
select
expand
patient
rrm
high
diseas
sever
score
might
repres
cellular
sword
damokl
follow
gener
could
key
pathogen
event
ms
cm
cell
probabl
longer
requir
consist
unexpect
failur
antibodi
inhibit
relaps
establish
rrm
summari
virusinduc
dc
matur
cytokin
product
could
lead
gener
potenti
pathogen
cm
cell
autoreact
memori
cell
constitut
present
healthi
individu
figur
genomewid
associ
studi
identifi
snp
loci
msassoci
risk
factor
cytokin
receptor
control
homeostasi
f
f
regulatori
th
cell
respect
also
essenti
protect
cell
respons
notabl
riskconf
snp
reduc
express
suggest
control
memori
cell
homeostasi
togeth
particularli
import
patient
ms
base
cell
repopul
studi
follow
therapeut
lymphocyt
deplet
antibodi
previous
propos
cell
homeostasi
might
disturb
ms
found
cm
cell
expand
patient
ms
high
diseas
score
convent
cell
select
decreas
particular
cm
cell
patient
treat
natalizumab
latter
unexpect
sinc
natalizumab
lead
accumul
proinflammatori
cell
circul
notabl
healthi
individu
cell
respond
virus
includ
jcv
convers
patient
rrm
cm
cell
fail
respond
jcv
instead
prolifer
spontan
autolog
dc
consequ
natalizumabassoci
decreas
cm
cell
might
explain
risk
patient
ms
develop
pml
follow
prolong
natalizumab
treatment
inde
patient
pml
ms
treat
natalizumab
impair
jcvspecif
respons
addit
studi
need
establish
whether
decreas
cm
cell
associ
risk
pml
could
mechan
select
shift
cell
analyz
patient
ms
among
cell
subset
express
high
level
tbet
induc
ifng
also
chain
consequ
render
cell
homeostasi
sensit
figur
importantli
persist
antivir
convent
memori
cell
requir
compet
lymphocyt
vivo
human
cm
prolifer
slowli
steadi
state
cell
contain
cm
cm
cell
express
highest
level
among
cm
prolifer
extens
absenc
tcr
stimul
thu
cm
cm
cell
expect
compet
secondari
lymphoid
organ
competit
could
intensifi
natalizumab
limit
access
peripher
tissu
bone
marrow
lung
note
lung
nich
rest
myelinreact
memori
cell
lewi
rat
eae
moreov
bone
marrow
key
site
memori
cell
mainten
human
antivir
cell
enrich
site
interestingli
natalizumab
inhibit
bone
marrow
home
stem
cell
although
unclear
whether
also
interfer
cell
home
bone
marrow
lung
lymph
node
dc
expect
expand
preferenti
autoreact
cm
cell
absenc
viral
reactiv
figur
inde
import
function
dc
present
selfmhc
cell
steadi
state
induc
cell
surviv
allow
secondari
expans
memori
cell
moreov
dc
also
transpres
lymphocyt
figur
includ
cell
could
induc
surviv
prolifer
antivir
cell
thu
competit
selfmhc
present
dc
lymph
node
possibl
mechan
wherebi
autoreact
pathogen
cm
cell
could
expand
select
cost
virusspecif
protect
cm
cell
patient
natalizumabtr
ms
figur
whatev
mechan
disequilibrium
would
render
patient
ms
vulner
relaps
also
jcv
summari
cell
homeostasi
appear
disturb
patient
ms
research
need
understand
mainten
relaps
could
trigger
viral
reactiv
cn
induc
recruit
autoreact
bystand
discuss
least
two
differ
pathway
could
lead
recruit
pathogen
cell
cn
consequ
relaps
one
hand
autoreact
cell
could
enter
cn
absenc
infect
via
hand
viral
reactiv
cn
could
induc
consequ
attract
autoreact
andor
virusspecif
cell
notabl
sinc
cell
coexpress
could
use
either
pathway
reach
cn
howev
antivir
cell
lack
express
strongli
enrich
csf
patient
activ
ms
suggest
axi
relev
relaps
consist
notion
circul
patient
ms
cn
home
block
natalizumab
select
increas
b
cell
cell
requir
differ
anim
model
ms
variabl
role
ms
suggest
fact
express
brain
lesion
patient
ms
snp
gene
locu
associ
wors
prognosi
healthi
individu
cell
respond
virus
express
thu
could
contribut
physiolog
antivir
immun
surveil
cn
figur
key
figur
convers
patient
ms
cell
respond
select
viral
myelinderiv
antigen
respect
suggest
cell
also
mediat
antivir
immun
respons
patient
ms
cell
could
attack
uninfect
tissu
promot
relaps
figur
scenario
relaps
could
trigger
viral
reactiv
lead
bystand
recruit
autoreact
cell
cn
via
ebv
one
obviou
candid
viru
induc
bystand
cell
recruit
high
frequenc
jcvspecif
cell
csf
patient
activ
ms
also
support
role
jcv
reactiv
relaps
bystand
recruit
model
import
implic
ms
therapi
predict
select
target
autoreact
cell
could
effici
natalizumab
therapi
would
induc
pml
antivir
cell
spare
surprisingli
littl
known
signal
induc
neurotrop
virus
switch
latenc
lytic
stage
therefor
stress
often
suggest
common
explan
case
jcv
tnfa
produc
effector
cell
upon
antigen
activ
deliv
critic
reactiv
signal
therefor
possibl
autoreact
cell
induc
de
novo
viral
reactiv
cn
thu
fuel
viciou
feedforward
loop
lead
recruit
new
wave
pathogen
cell
possibl
also
virusinfect
b
cell
altern
possibl
autoreact
cell
home
first
cn
remiss
phase
ms
via
induc
viral
reactiv
recruit
antivir
cell
via
figur
howev
latter
model
fail
fulli
explain
relaps
characterist
patient
ms
sinc
healthi
individu
also
harbor
autoreact
f
f
cell
produc
substanti
amount
gmcsf
also
case
concomit
enrich
virusspecif
myelinreact
cell
csf
patient
activ
ms
underlin
close
relationship
antivir
immun
respons
ms
warrant
investig
infect
promot
autoimmun
diseas
fascin
clinic
relev
topic
ms
field
domin
search
singl
caus
infecti
agent
due
strong
epidemiolog
evid
ebv
attract
attent
intrigu
molecular
mimicri
hypothesi
underlin
possibl
role
ebv
howev
accumul
evid
indic
sever
neurotrop
virus
includ
jcv
could
role
ms
also
possibl
differ
virus
could
import
individu
patient
ms
review
discuss
poorli
understood
intens
debat
understudi
aspect
field
propos
possibl
mechan
viral
infect
could
gener
pathogen
cm
cell
autoreact
memori
cell
upon
bystand
activ
cm
cell
could
progress
expand
cost
protect
antivir
cell
remiss
phase
could
final
recruit
cn
upon
viral
reactiv
promot
relaps
notabl
molecular
mimicri
concept
bystand
generationrecruit
model
mutual
exclus
howev
find
jcvspecif
autoreact
cell
patient
ms
larg
segreg
two
differ
subset
cell
differ
properti
suggest
select
target
cell
could
inhibit
relaps
without
induc
pml
research
antivir
immun
respons
anim
model
ms
patient
necessari
unravel
bloodbrain
barrier
bloodbrain
barrier
bloodbrain
barrier
bloodbrain
barrier
bloodbrain
barrier
antivir
cell
rapidli
control
viru
tissu
repair
mechan
ensur
damag
cn
limit
relaps
could
trigger
immun
surveil
mechan
lead
erron
bystand
recruit
autoreact
cm
cell
cn
patient
multipl
sclerosi
ms
addit
infect
b
cell
could
recruit
transport
virus
epsteinbarr
viru
ebv
john
cunningham
viru
jcv
cn
cm
cell
patient
ms
healthi
individu
react
myelinderiv
selfantigen
thu
could
attack
healthi
uninfect
tissu
induc
extens
tissu
damag
relaps
iii
b
altern
autoreact
cm
cell
could
home
spontan
cn
parenchyma
via
remiss
phase
patient
ms
induc
de
novo
viral
reactiv
consequ
recruit
lymphocyt
ii
reactiv
virus
cn
induc
autoreact
cm
cell
could
either
trigger
relaps
repres
amplif
loop
virusinduc
relaps
notabl
autoreact
cell
healthi
individu
could
also
induc
viral
reactiv
cn
mechan
less
pathogen
complex
relationship
virus
ms
predict
relaps
ultim
develop
effici
andor
select
therapi
